Your browser doesn't support javascript.
loading
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.
Yao, James C; Phan, Alexandria T; Chang, David Z; Wolff, Robert A; Hess, Kenneth; Gupta, Sanjay; Jacobs, Carmen; Mares, Jeannette E; Landgraf, Andrea N; Rashid, Asif; Meric-Bernstam, Funda.
Affiliation
  • Yao JC; Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. jyao@mdanderson.org
J Clin Oncol ; 26(26): 4311-8, 2008 Sep 10.
Article in En | MEDLINE | ID: mdl-18779618
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Octreotide / Antineoplastic Combined Chemotherapy Protocols / Neuroendocrine Tumors / Sirolimus Type of study: Guideline Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Clin Oncol Year: 2008 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Octreotide / Antineoplastic Combined Chemotherapy Protocols / Neuroendocrine Tumors / Sirolimus Type of study: Guideline Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Clin Oncol Year: 2008 Document type: Article Affiliation country: United States Country of publication: United States